SVB Leerink Downgrades ChemoCentryx to Market Perform, Lowers Price Target to $52
Benzinga Newsdesk 4 years ago
NewsDowngradesPrice TargetAnalyst Ratings
SVB Leerink analyst Joseph Schwartz downgrades ChemoCentryx (NASDAQ:CCXI) from Outperform to Market Perform and lowers the price target from $64 to $52.
SVB Leerink analyst Joseph Schwartz downgrades ChemoCentryx (NASDAQ:CCXI) from Outperform to Market Perform and lowers the price target from $64 to $52.